RP1-104: IGNYTE-3: A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician's Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen

IGNYTE-3: A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician's Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen
Principal Investigator
Kolodney, Joanna
Phase
III
Age Group
Adult
Applicable Disease Sites
Melanoma and Other Skin Cancers
Participating Institutions
Mary Babb Randolph Cancer Center
Contacts
Meg Zafiris
Research Specialist
Email:

View on ClinicalTrials.gov

Quick Search

Use the full search for additional searching options.